[YTLPOWR] YoY Annual (Unaudited) Result on 30-Jun-2020 [#4] | Financial Results | I3investor

[YTLPOWR] YoY Annual (Unaudited) Result on 30-Jun-2020 [#4]

Announcement Date
28-Aug-2020
Admission Sponsor
-
Sponsor
-
Financial Year
30-Jun-2020
Quarter
30-Jun-2020 [#4]
Profit Trend
YoY- -85.95%
View:
Show?
Annual (Unaudited) Result
30/06/23 30/06/22 30/06/21 30/06/20 30/06/19 30/06/18 30/06/17 CAGR
Revenue 21,892,529 17,793,900 10,782,762 10,670,263 11,677,077 10,589,669 9,778,239 14.37%
PBT 2,443,215 1,396,434 636,457 423,778 733,691 943,244 867,617 18.82%
Tax -416,818 -173,614 -735,116 -298,175 -145,881 -226,364 -112,957 24.29%
NP 2,026,397 1,222,820 -98,659 125,603 587,810 716,880 754,660 17.88%
-
NP to SH 2,021,959 1,257,591 -143,065 64,573 459,479 620,658 673,407 20.10%
-
Tax Rate 17.06% 12.43% 115.50% 70.36% 19.88% 24.00% 13.02% -
Total Cost 19,866,132 16,571,080 10,881,421 10,544,660 11,089,267 9,872,789 9,023,579 14.05%
-
Net Worth 16,771,458 14,340,814 13,044,472 11,973,467 12,664,248 13,144,950 13,251,162 4.00%
Dividend
30/06/23 30/06/22 30/06/21 30/06/20 30/06/19 30/06/18 30/06/17 CAGR
Div 486,129 364,596 364,597 - 383,765 395,932 387,460 3.85%
Div Payout % 24.04% 28.99% 0.00% - 83.52% 63.79% 57.54% -
Equity
30/06/23 30/06/22 30/06/21 30/06/20 30/06/19 30/06/18 30/06/17 CAGR
Net Worth 16,771,458 14,340,814 13,044,472 11,973,467 12,664,248 13,144,950 13,251,162 4.00%
NOSH 8,158,208 8,158,208 8,158,208 8,158,208 8,158,208 8,158,208 7,749,217 0.86%
Ratio Analysis
30/06/23 30/06/22 30/06/21 30/06/20 30/06/19 30/06/18 30/06/17 CAGR
NP Margin 9.26% 6.87% -0.91% 1.18% 5.03% 6.77% 7.72% -
ROE 12.06% 8.77% -1.10% 0.54% 3.63% 4.72% 5.08% -
Per Share
30/06/23 30/06/22 30/06/21 30/06/20 30/06/19 30/06/18 30/06/17 CAGR
RPS 270.21 219.62 133.09 139.02 152.14 133.73 126.18 13.52%
EPS 24.96 15.52 -1.80 0.84 5.98 7.89 8.69 19.21%
DPS 6.00 4.50 4.50 0.00 5.00 5.00 5.00 3.08%
NAPS 2.07 1.77 1.61 1.56 1.65 1.66 1.71 3.23%
Adjusted Per Share Value based on latest NOSH - 8,158,208
30/06/23 30/06/22 30/06/21 30/06/20 30/06/19 30/06/18 30/06/17 CAGR
RPS 264.81 215.23 130.43 129.07 141.24 128.09 118.28 14.36%
EPS 24.46 15.21 -1.73 0.78 5.56 7.51 8.15 20.09%
DPS 5.88 4.41 4.41 0.00 4.64 4.79 4.69 3.83%
NAPS 2.0287 1.7346 1.5778 1.4483 1.5319 1.59 1.6028 4.00%
Price Multiplier on Financial Quarter End Date
30/06/23 30/06/22 30/06/21 30/06/20 30/06/19 30/06/18 30/06/17 CAGR
Date 30/06/23 30/06/22 30/06/21 30/06/20 28/06/19 29/06/18 30/06/17 -
Price 1.30 0.685 0.695 0.67 0.82 1.03 1.45 -
P/RPS 0.48 0.31 0.52 0.48 0.54 0.77 1.15 -13.54%
P/EPS 5.21 4.41 -39.36 79.64 13.70 13.14 16.69 -17.63%
EY 19.20 22.66 -2.54 1.26 7.30 7.61 5.99 21.41%
DY 4.62 6.57 6.47 0.00 6.10 4.85 3.45 4.98%
P/NAPS 0.63 0.39 0.43 0.43 0.50 0.62 0.85 -4.86%
Price Multiplier on Announcement Date
30/06/23 30/06/22 30/06/21 30/06/20 30/06/19 30/06/18 30/06/17 CAGR
Date 24/08/23 25/08/22 08/09/21 28/08/20 29/08/19 29/08/18 29/08/17 -
Price 1.75 0.72 0.715 0.69 0.685 1.09 1.43 -
P/RPS 0.65 0.33 0.54 0.50 0.45 0.82 1.13 -8.80%
P/EPS 7.01 4.64 -40.49 82.02 11.44 13.91 16.46 -13.25%
EY 14.26 21.56 -2.47 1.22 8.74 7.19 6.08 15.25%
DY 3.43 6.25 6.29 0.00 7.30 4.59 3.50 -0.33%
P/NAPS 0.85 0.41 0.44 0.44 0.42 0.66 0.84 0.19%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ & YoY figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment